A Randomized Study on CNS Prophylaxis With Liposome-Encapsulated Cytarabine in Association With a Lineage-Targeted and MRD-Oriented Postremission Strategy in Adult ALL

Trial Profile

A Randomized Study on CNS Prophylaxis With Liposome-Encapsulated Cytarabine in Association With a Lineage-Targeted and MRD-Oriented Postremission Strategy in Adult ALL

Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Cytarabine (Primary) ; Asparaginase; Methotrexate; Prednisone
  • Indications Acute lymphoblastic leukaemia; Brain metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Dec 2016 Final results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Dec 2013 Results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
    • 31 Mar 2011 Planned end date changed from 1 Jan 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top